Needham reiterates Buy rating on Ocular Therapeutix, $18 price target

Ocular Therapeutix (OCUL) plans to file for FDA approval of AXPAXLI in Q4, following positive SOL-1 trial results. The company discussed trial design and competitive developments, highlighting patient selection and trial design importance. OCUL has $600M in cash and expects runway into 2028. They are preparing for a potential AXPAXLI launch.

Ocular Therapeutix (OCUL) presented at Chardan's conference, highlighting its wet AMD drug AXPAXLI. The company reported SOL-1 trial success, a clear FDA path, and $600M cash runway. Management emphasized AXPAXLI's maintenance-therapy model and competitive advantages. OCUL shares rose 4.13% to $6.55.

Ocular Therapeutix announced that Sanjay Nayak resigned as Chief Strategy Officer, effective October 16, 2026, to become CEO of a private company. No replacement was disclosed.

UBS initiated coverage on Ocular Therapeutix (OCUL) with a buy rating and $14 price target, citing Axpaxli's potential in retinal therapy. The stock trades at $7.54, with UBS modeling $3.3B in 2035 sales. Positive Phase 3 trial results and regulatory updates are expected. Analysts remain optimistic despite competitor setbacks and delayed trial readouts.

Ocular Therapeutix (OCUL) shares dropped 22% as competitors Kodiak Sciences (KOD) and 4D Molecular Therapeutics (FDMT) reported positive updates on their wet AMD treatments. KOD's DAYBREAK study met goals, while FDMT's 4D-150 showed lasting benefits. OCUL's AXPAXLI is in development, with FDA filing planned for late 2026.

Ocular Therapeutix (OCUL) reported a positive Pre-NDA Meeting with the FDA for AXPAXLI, a treatment for wet AMD, and plans to file an NDA in Q4 2026. The company aims to use Phase 3 SOL-1 efficacy and interim SOL-R safety data. Analysts forecast revenue of $460.1M and earnings of $100.9M by 2029, with a 176% potential upside. The key risks include execution, long-term safety, and commercialization.